Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Buy” by the twenty-six brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $72.38.
A number of brokerages have commented on DXCM. Wedbush restated a “buy” rating and issued a $76.00 price target on shares of DexCom in a research report on Wednesday, October 4th. Leerink Swann reiterated a “buy” rating and set a $57.00 target price (down previously from $85.00) on shares of DexCom in a research report on Friday, September 29th. Raymond James Financial, Inc. cut DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. ValuEngine cut DexCom from a “hold” rating to a “sell” rating in a research report on Thursday, September 28th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $87.00 target price on shares of DexCom in a research report on Thursday, September 28th.
COPYRIGHT VIOLATION NOTICE: “Brokerages Set DexCom, Inc. (DXCM) Target Price at $72.38” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://sportsperspectives.com/2017/10/10/brokerages-set-dexcom-inc-dxcm-target-price-at-72-38.html.
DexCom (DXCM) traded down 2.50% on Friday, reaching $46.10. The company’s stock had a trading volume of 2,403,475 shares. The stock’s market cap is $3.99 billion. The stock has a 50-day moving average of $66.93 and a 200-day moving average of $71.75. DexCom has a one year low of $42.62 and a one year high of $88.80.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.24) earnings per share. On average, analysts predict that DexCom will post ($0.80) EPS for the current fiscal year.
In other news, EVP Andrew K. Balo sold 3,244 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $71.18, for a total value of $230,907.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $71.86, for a total value of $431,160.00. The disclosure for this sale can be found here. Insiders sold a total of 29,023 shares of company stock valued at $2,056,178 over the last ninety days. Corporate insiders own 1.70% of the company’s stock.
Several large investors have recently bought and sold shares of DXCM. BNP Paribas Arbitrage SA lifted its stake in shares of DexCom by 238.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,476 shares of the medical device company’s stock valued at $379,000 after purchasing an additional 3,155 shares during the last quarter. UBS Asset Management Americas Inc. lifted its stake in shares of DexCom by 14.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 248,178 shares of the medical device company’s stock valued at $21,028,000 after purchasing an additional 30,737 shares during the last quarter. Karp Capital Management Corp bought a new stake in shares of DexCom in the 1st quarter valued at approximately $631,000. KBC Group NV lifted its stake in shares of DexCom by 35.5% in the 1st quarter. KBC Group NV now owns 8,308 shares of the medical device company’s stock valued at $704,000 after purchasing an additional 2,177 shares during the last quarter. Finally, Prudential Financial Inc. lifted its stake in shares of DexCom by 15.6% in the 1st quarter. Prudential Financial Inc. now owns 117,338 shares of the medical device company’s stock valued at $9,942,000 after purchasing an additional 15,800 shares during the last quarter.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.